DHEA in Synovial Sarcoma Patients
Conditions: Synovial Sarcoma; Sarcoma, SynovialInterventions: Drug: DHEA; Other: FACT-67 validated surveySponsor: Washington University School of MedicineNot yet recruiting - verified February 2016 (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 11, 2016 Category: Research Source Type: clinical trials
A Phase 1 Study of the EZH2 Inhibitor Tazemetostat in Pediatric Subjects With Relapsed or Refractory INI1-Negative Tumors or Synovial Sarcoma
Conditions: Rhabdoid Tumors; INI1-negative Tumors; Synovial Sarcoma; Malignant Rhabdoid Tumor of OvaryIntervention: Drug: TazemetostatSponsor: Epizyme, Inc.Not yet recruiting - verified November 2015 (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 21, 2015 Category: Research Source Type: clinical trials
A Phase II, Multicenter Study of the EZH2 Inhibitor Tazemetostat in Adult Subjects With INI1-Negative Tumors or Relapsed/Refractory Synovial Sarcoma
Conditions: Malignant Rhabdoid Tumors (MRT); Rhabdoid Tumors of the Kidney (RTK); Atypical Teratoid Rhabdoid Tumors (ATRT); Selected Tumors With Rhabdoid Features; Synovial Sarcoma; INI1-negative Tumors; Malignant Rhabdoid Tumor of OvaryIntervention: Drug: TazemetostatSponsor: Epizyme, Inc.Not yet recruiting - verified November 2015 (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 21, 2015 Category: Research Source Type: clinical trials
A Phase 1 Study of the EZH2 Inhibitor Tazemetostat in Pediatric Subjects With Relapsed or Refractory INI1-Negative Tumors or Synovial Sarcoma
Conditions: Rhabdoid Tumors; INI1-negative Tumors; Synovial Sarcoma; Malignant Rhabdoid Tumor of OvaryIntervention: Drug: TazemetostatSponsor: Epizyme, Inc.Not yet recruiting - verified November 2015 (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 21, 2015 Category: Research Source Type: clinical trials
